A Phase 1 Placebo-Controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Multiple Escalating Oral Doses Of PF-04620110 In Otherwise Healthy Overweight And Obese Adult Subjects.
Phase of Trial: Phase I
Latest Information Update: 12 Jun 2012
At a glance
- Drugs PF 4620110 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 12 Jun 2012 Results presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.
- 24 May 2010 Actual patient number (71) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History